Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Operating Leases (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Operating Leases for 2 consecutive years, with $15.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 1.83% to $15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2025, down 1.83% year-over-year, with the annual reading at $15.0 million for FY2025, 1.83% down from the prior year.
  • Operating Leases hit $15.0 million in Q4 2025 for Prelude Therapeutics, down from $15.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $18.1 million in Q3 2024 to a low of $15.0 million in Q4 2025.